Hyperamylasemia During Omalizumab Therapy

Creative Commons License

Karabiber E., Aktas O. O., Ozdemir E., DAMADOĞLU E., ŞAHİNER Ü. M., KARAKAYA G., ...More

ASTIM ALLERJI IMMUNOLOJI, vol.20, no.1, pp.31-35, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.21911/aai.650
  • Journal Name: ASTIM ALLERJI IMMUNOLOJI
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.31-35
  • Keywords: Amylase, anti-IgE, asthma, urticaria, omalizumab, ANTI-IGE ANTIBODY, AMYLASE
  • Hacettepe University Affiliated: Yes

Abstract

Objective: Omalizumab safety studies have shown that the drug has an excellent safety profile and is well tolerated in patients with asthma and chronic idiopatic urticaria (CIU) with no blood chemistry monitoring during treatment. Although our clinical experience with drug has pointed out abnormalities in amylase levels. The aim of the present study is to assess blood amylase values during omalizumab therapy and to explain if there is an association between omalizumab therapy and high serum amylase levels.